title: Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
abstract: The authors describe a male patient who developed a large intracranial meningioma during the hormone therapy for pre-existing prostate cancer. A 70-year-old man received a brain check-up, and no intracranial abnormality was detected. Five months later, prostate cancer was diagnosed, and he underwent prostatectomy. Leuprorelin acetate, a luteinizing hormone-releasing hormone (LH-RH) agonist, was subsequently administered to the patient once a month for 3 years. After that he presented with a large parasagittal mass, which was excised. The tumor was histologically diagnosed as meningothelial meningioma, and LH-RH receptors were verified immunohistochemically in the cytoplasm of the tumor cells. Leuprorelin acetate may accelerate the rapid growth of meningioma in this patient.
authors.affiliation: Department of Neurosurgery, Shunan Memorial Hospital.
authors.forename: Takeo
authors.initials: T
authors.lastname: Anda
authors.forename: Masaru
authors.initials: M
authors.lastname: Honda
authors.forename: Tokuhiro
authors.initials: T
authors.lastname: Ishihara
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kamei
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000813:Anilides / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005743:Gastrectomy; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000139:chemically induced* / Q000737:chemistry / Q000473:pathology; D008579:Meningioma / Q000139:chemically induced* / Q000737:chemistry / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced* / Q000737:chemistry / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000473:pathology; D009570:Nitriles / Q000008:administration & dosage; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011974:Receptors, LH / Q000032:analysis; D013274:Stomach Neoplasms / Q000601:surgery; D014105:Tosyl Compounds / Q000008:administration & dosage
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009363:Neoplasm Proteins; D009570:Nitriles; D011974:Receptors, LH; D014105:Tosyl Compounds; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide; D016729:Leuprolide